Pharming Group N.V. (PHAR)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Pharming Group N.V. — 6-K Filing
# 📄 What This Document Is This is a **Form 6-K**, a special report that foreign companies (like this Dutch one) must file with the U.S. Securities and Exchange Commission (SEC) when they release important news to investors in their home country. Think of it as an official "news alert" for America
SEC filings
All filings →Insider trades
All insider trades →Pharming Group N.V. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Pharming Group N.V.
All people →No officers or directors have been indexed for Pharming Group N.V..